Arranta Bio provides contract development and manufacturing services to pioneering innovators working on new therapies targeting diseases linked to the human microbiome.
Arranta Bio is delivering on its vision to build the best-in-class microbiome contract development and manufacturing organization (CDMO) through our merger with a 10-year veteran CDMO, Captozyme, and the establishment of a commercial-ready manufacturing facility.
Our aim is to support the pioneers in the development of healthcare therapies based on live biotherapeutic products (LBPs) targeting gut health and microbiome-related diseases by providing development and manufacturing services that bring effective treatments to the market and patients in need.
Over a 10-year period, Captozyme produced over 125 species and amassed a deep understanding of the manufacturing needs for live biopharmaceuticals, whether that be obligate, facultative or microaerophilic organisms.
Arranta Bio was formed in May 2019 with the vision to be the best-in-class microbiome CDMO. In October 2019, we completed an $82,000,000 funding round with sole institutional investor, Ampersand Capital, company founders and colleagues, and a strategic investment from Thermo Fisher ScientificRead the full press release
In November 2019, Arranta Bio merged with Captozyme to form a microbiome therapy-focused CDMO that supports clients from early-stage process development through cGMP clinical supply to commercialization.Read the full press release
The microbiome – literally trillions of bacteria, fungi, protozoa and viruses living in and on the human body – has been called the second genome. Over the last decade, there has been rapid acceleration in scientific understanding of its composition and functions.
Today, around 200 companies are focused on understanding the human microbiome and its linkage to areas including infectious diseases and oncology to identify therapeutic targets. Arranta Bio is building a CDMO to support these innovators at the frontier of this exciting new sphere of medicine.
Arranta Bio offers process development and cGMP manufacture of live biotherapeutic products (LBPs) for clinical and commercial supply.
We’re always open to engaging with people interested in our company or the microbiome therapy market in general.
We look forward to hearing from you.